tradingkey.logo

Outlook Therapeutics Inc <OTLK.OQ> expected to post a loss of 60 cents a share - Earnings Preview

ReutersMay 12, 2025 1:58 PM
  • Outlook Therapeutics Inc OTLK.OQ OTLK.O is expected to show a rise in quarterly revenue when it reports results on May 14 (estimated) for the period ending March 31 2025

  • The Iselin New Jersey-based company is expected to report revenue of $702.6 thousand, according to the mean estimate from 5 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Outlook Therapeutics Inc is for a loss of 60 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Outlook Therapeutics Inc is $9.50​, above​ its last closing price of $1.53. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.69

-0.77

0.72

Beat

192.9

Sep. 30 2024

-0.86

-0.83

0.76

Beat

191.1

Jun. 30 2024

-1.02

-1.00

-0.83

Beat

16.8​

Mar. 31 2024

-0.96

-0.85

-1.55

Missed

-82.4

​​Dec. 31 2023

-0.92

-1.00

-0.80

Beat

20

Sep. 30 2023

-1.16

-1.17

-1.00

Beat

14.9​

Jun. 30 2023

-0.82

-1.03

-1.60

Missed

-55.6

Mar. 31 2023

-1.19

-1.30

-0.60

Beat

53.8

This summary was machine generated May 12 at 13:58 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI